Connor, Clark & Lunn Investment Management Ltd. Amylyx Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 1,263,353 shares of AMLX stock, worth $4.17 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,263,353
Previous 880,745
43.44%
Holding current value
$4.17 Million
Previous $2.85 Million
66.91%
% of portfolio
0.02%
Previous 0.02%
Shares
6 transactions
Others Institutions Holding AMLX
# of Institutions
142Shares Held
49.1MCall Options Held
281KPut Options Held
438K-
Perceptive Advisors LLC New York, NY6.77MShares$22.4 Million0.85% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$15.3 Million2.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.69MShares$8.89 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$8.81 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$8.01 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $193M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...